in 2003 and involved more than 16,000 volunteers, men d women age18 to 30 at average risk becoming infeed. for three years, half were given the vaccines. the otr half, placebo injections andere monitor for anoth three years. both drugs stimulate dferent aspects of the immune stem to fight hiv but had been deemed ilures on their own. vaccine one alvac uses a disabled poxvirus with genetic materialrom hiv inserted into it. it prompts th bodies toake "t" cells kill the infection. vaccine contns an h protein lled gp20. it encourages the body to produce antibodies to dstroy v before the virus can infect healy cells. us together, there's a 31.2% lowerisk of infection. >> this is the first time we c improve the vaccine mproves infection -- which is the fst stepping-stone for furer vaccine developmen >> 31% isxtremely low for a vaccinand there's concern abouhowffordable and fective they could be on the scale needed in asia and b-saharan rica. 2 million peopleied of aids in 07. nely 7,000 are infecwith hiv every y. with sexual behavior a big part of the problem, could hopes of a vaccine encourage